Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-12-17-Speech-3-247"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20031217.8.3-247"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:translated text |
".
The decisions on the Fifth and Sixth Framework Programmes for Community research and their respective specific programmes do not make any provision for the allocation of a budget specifically devoted to embryonic stem cell research.
As regards the Fifth Framework Programme, there are two research projects which include activities in which it is planned to use human embryonic stem cell lines. As for the Sixth Framework Programme, on the one hand no project has to date received funding for this type of research and, on the other hand, only one project involving an aspect of research using a line of human embryonic stem cells is a possible contender for selection following the initial call for proposals. All the cell lines in question are existing lines and were created without the use of Community funding and outside the European Union.
The Commission does not have any other information, particularly as regards the quantity of human embryos that might be used in Member States for obtaining stem cells. Those Member States who authorise and regulate the use of human embryos for obtaining stem cells are currently Belgium, Denmark, Spain, Finland, France, Greece, the Netherlands, Sweden and the United Kingdom.
Decisions on the Fifth and Sixth Framework Programmes and their respective specific programmes authorise the financing of research into stem cells of any origin.
The European Parliament, in its resolution of 19 November this year, came out in favour of Community funding for research activities using both embryonic stem cells and adult stem cells."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples